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Summary
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activ-
ation, has been approved by the Swiss health regulatory
agency Swissmedic for the treatment of active rheumatoid
arthritis (RA). This article summarises the key trial find-
ings for this biologic agent in RA in different situations
such as early erosive rheumatoid arthritis (RA), biologic-
naïve RA, RA before and after the use of methotrexate or
TNF-inhibitors and includes safety information from these
trials. Based on these data, recommendations for clinical
practice in Switzerland are made by a panel of experts.
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Introduction
Abatacept was approved by the Swiss health regulatory
agency Swissmedic in August 2007 and is reimbursed by
health insurance plans for the treatment of active rheum-
atoid arthritis (RA) “not sufficiently responsive to disease
modifying antirheumatic drugs (DMARD) such as metho-
trexate (MTX) or TNF inhibitors”. Abatacept may be used
as a first line biologic agent in Switzerland.
Experts from leading Swiss rheumatological centres have
convened for a joint analysis of the relevant, including the
most recent, published phase 2 and 3 as well as open exten-
sion trials.
This article summarises the key trial findings for abatacept
in RA in different situations such as early erosive RA,
biologic-naïve RA, RA before and after the use of MTX or
TNF inhibitors and includes safety information from these
trials.
The article closes with the experts’ conclusions and recom-
mendations, based on the clinical data presented and the
experts’ experience with abatacept in clinical practice.
Mode of action of abatacept
Abatacept’s mode of action is distinct from all other avail-
able DMARDs and biologics [1]. The molecule is a human
protein designed to selectively inhibit T-cell activation, a
process that plays a central role in the immunopathogenesis
of RA [2]. Subsequent to antigen recognition via the major
histocompatibility complex on antigen-presenting cells by
Figure 1
Mode of action of abatacept. By binding to CD80/86, abatacept
blocks the interaction of CD80/86 and CD28 on the APC and T cell,
respectively. The co-stimulatory pathway leading to T-cell activation
is inhibited and processes in the inflammatory cascade are
downregulated, resulting in normalized levels of cytokines and
autoantibodies, and inhibition of osteoclast activity. APC: antigen
presenting cell (e.g., macrophages, dendritic cells, B cells); MHC:
major histocompatibility complex; TCR: T-cell receptor; RF:
rheumatoid factor; TNF: tumour necrosis factor; IFN: interferon; IL:
interleukin; anti-CCP: anti-cyclic citrullinated peptide; RANK:
receptor activator of NF-κB; MMPs: matrix metalloproteinases.
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the T-cell receptor [3, 4], T-cells require a second, so-called
co-stimulatory signal for full activation (fig. 1). Abatacept,
as a humanised CTLA-4-immunoglublin-Fc (CTLA-4-Ig)
fusion protein, selectively modulates T-cell co-stimulation.
It prevents activation of T-cells by binding to the natural
ligands CD 80 and CD86. In consequence, CD80 and
CD86 cannot interact with CD28 on the T lymphocyte. As
an important indirect effect within the inflammatory casca-
de, the production of cytokines and autoantibodies is inhib-
ited (fig. 1) [2]. Studies confirmed the broad influence of
abatacept on both serum and synovial biomarkers, with re-
ductions in the levels of IFNγ, TNF-α, IL-6, matrix metal-
loproteinase (MMP)-1 and -2, RF and other cytokines [5,
6].
Abatacept in early erosive RA with
poor prognostic factors
The AGREE trial evaluated the efficacy and safety of
abatacept in MTX-naive patients with early RA (mean dis-
ease duration 6 to 7 months) and poor prognostic factors
[7]. A total of 509 patients were randomised 1:1 to receive
abatacept plus MTX or placebo plus MTX for 1 year. Mean
DAS28 (CRP) was 6.3 at study entry and radiographic
evidence of joint destruction was present in all patients. All
patients were RF and/or anti-CCP positive. At year 1, dis-
ease activity as well as damage was significantly lower in
the patients with active treatment.
The overall drug retention rate was 94.3% in the second
year [8]. This value is extraordinarily high. It could be ex-
plained in part if a high percentage of patients were re-
cruited in countries with limited access to other biologic
agents. 91.1% of patients on abatacept plus MTX who
showed no radiographic progression at the end of year 1
remained non-progressors at the end of year 2. Similar to
studies with TNF inhibitors, the positive effects of abata-
cept on the inhibition of radiographic progression was in-
dependent of disease activity or physical functions [9].
Abatacept in biologic-naïve patients
Abatacept in combination with MTX in biologic-naïve pa-
tients with active RA and an inadequate response to MTX
has been assessed in one phase IIb study and two large
phase III studies.
In the AIM trial, the clinical response after 6 months was
significantly higher with abatacept as compared to placebo,
and the ACR response rates continued to improve up to 12
months only in the abatacept arm [10, 11]. Over 90% of the
patients receiving abatacept plus MTX who achieved mod-
erate disease activity after 3 months had a sustained or even
improved outcome regarding low disease activity (LDAS)
or DAS28 (ESR)-defined remission at 6 and 12 months.
In the ATTEST study, patients with an inadequate response
to MTX continued taking MTX and additionally received
abatacept, infliximab, or placebo [12]. After 6 months of
treatment, abatacept plus MTX significantly reduced the
signs and symptoms of RA compared with placebo plus
MTX. Similar results were seen in the infliximab plus
MTX group. However, the proportions of patients achiev-
ing good EULAR response, LDAS, and DAS28 (ESR)-
defined remission continued to increase with abatacept plus
MTX, whereas the response to infliximab-based treatment
stabilised. After 12 months, a greater reduction in DAS28
(ESR) was observed with abatacept plus MTX than with
infliximab plus MTX (–2.88 vs. –2.25).
Radiographic progression
In the AIM trial, radiographic data were available for 92%
of patients [10]. At the end of year 1, the slowing of joint
destruction was significantly greater with abatacept plus
MTX as compared to placebo plus MTX. The analysis of
radiographic data from AIM over 5 years indicates that
abatacept plus MTX may have an increasing beneficial ef-
fect on structural damage over time in the majority of ini-
tially responding patients [13]. Importantly, almost half of
the patients treated with abatacept in the study remained
free of progression over 5 years (change in radiographic
total score of ≤0 vs. baseline). The chance of remaining
free of progression within one more year increased with the
length of the previous period of non-progression.
Abatacept in patients failing prior
anti-TNF therapy
Several trials investigated abatacept in patients without pri-
or therapy with other biologics.
As expected, therapy with abatacept plus MTX resulted in
significantly greater improvements in ACR response and
DAS28 remission rates than MTX alone [14]. As shown
in the double-blind period of the ATTAIN trial in patients
with long-standing disease and failure of at least one pre-
vious anti-TNF therapy, therapy with abatacept plus MTX
resulted in significantly greater improvements in ACR re-
sponse and DAS28 remission rates than MTX alone [15].
After completing the 6-month double-blind period, patients
entering an open-label period continued to improve in dis-
ease status over the subsequent 4 years. The efficacy of
abatacept after anti-TNF failure was also investigated in
the open-label long-term extension of the ATTEST trial
[16]. Of the 27 patients who were in high disease activity
(HDAS) after 1 year of infliximab treatment, 81.5%
showed moderate (MDAS) or low (LDAS) disease activity
or were in remission 1 year after initiation of treatment with
abatacept.
In the ARRIVE trial, the safety, tolerability and efficacy
of switching directly from anti-TNF to abatacept was com-
pared to a scheme with a washout period of anti-TNF [17].
In the washout group, anti-TNF treatment was stopped at
least 2 months prior to abatacept treatment, while patients
in the direct switch group received the first abatacept dose
at the next scheduled anti-TNF therapy dose. The outcome
in terms of safety, tolerability, and efficacy was comparable
with or without a washout, thus supporting a direct switch
to abatacept after anti-TNF treatment as an option in clin-
ical practice.
Onset of action
In the AGREE trial, Durez and colleagues evaluated the
time course of improvement in ACR core components with
abatacept plus MTX or MTX alone over 12 months in pa-
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tients with early RA and poor prognostic factors [18]. The
median duration to achieve 50% improvement in individu-
al ACR core components was 1 to 4 months in the abata-
cept plus MTX group (fig. 2). CRP levels, joint counts
and physician’s assessment of disease activity were the
first ACR core components to demonstrate meaningful im-
provements within 2 months.
Predictability of clinical outcome based on evaluation
at 3 months
Westhovens and colleagues investigated the predictive
value of achieving a particular disease state with abatacept
after 3 months with respect to the outcome after 1 year [19].
Most patients achieving remission at the end of month 3
maintained this state at the end of month 12 (89.7%). Two-
thirds of the patients with a good response to treatment at
month 3 (LDAS) achieved remission at month 12 (67.9%).
Of the patients with a moderate response to treatment at
month 3 (MDAS), 61.4% achieved LDAS or remission at
month 12.
Maintenance therapy with abatacept
Westhovens and colleagues examined the sustained reduc-
tion of disease activity, inhibition of X-ray progression and
improvements in physical function and health-related qual-
ity of life (HRQoL) in patients treated with abatacept [20].
The analysis was based on 378 patients entering the long-
term extension phase of the AIM trial after completing the
first year of double-blind treatment. The proportion of pa-
tients with low disease activity at the end of year 1 and sus-
taining it from year 1 to year 5 was 71.2%, while 60.3%
of patients in remission at the end of year 1 remained in
remission also from year 1 to year 5. Similar results were
obtained for HAQ-DI normalisation rates and radiograph-
ic non-progression. Overall, approximately two-thirds of
patients maintained clinical remission, radiographic non-
progression, and normalisation of physical function and
HRQoL over 5 years of treatment. The authors concluded
that abatacept can provide sustained disease modification
and restore normal physical function in patients with RA.
Safety of abatacept
Serious adverse events
Data from eight clinical trials comprising 4,149 patients
with 12,132 patient-years of exposure up to 7 years demon-
strate abatacept’s good tolerability [21]. The types and the
Figure 2
Median time to at least 50% improvement in individual ACR core
components (LOCF). Figure based on data of the AGREE study as
reported by Durez et al. [18]. CRP: C-reactive protein; TJC: tender
joint count; SJC: swollen joint count; MDGA: physician’s global
assessment; PGA: patient’s global assessment.
frequency of safety events were consistent between short
term and long term treatment periods, indicating that the
safety profile of abatacept remains stable. The incidence of
serious adverse events was comparable to that of placebo.
This is in line with a recent Cochrane review which reports
a significantly lower risk of serious adverse events with
abatacept than with most other biologics [22].
Severe and opportunistic infections
Smitten and colleagues evaluated the risk of serious infec-
tions (opportunistic infections included) in 4,149 RA pa-
tients enrolled in abatacept clinical trials with a total of
11,658 patient-years of exposure [23]. The incidence rates
(IRs) of serious infection and hospitalised infection were
2.87 and 2.64/100 patient-years respectively. The most
common serious infections were pneumonia, urinary tract
infection and cellulitis. There were few opportunistic in-
fections with seven cases of tuberculosis. The frequency of
serious infections remained relatively stable over time.
Malignancies
In the same cohort of patients the IRs (per 100 patient-
years) of total malignancies, non-melanoma skin cancer
(NMSC), solid tumours, lung cancer and lymphoma were
1.41, 0.74, 0.57, 0.15 and 0.07/100 patient-years respect-
ively [23]. On the basis that the expected incidence rates
for certain malignancies such as lung cancer and lymph-
oma are generally higher in RA patients, Smitten et al. con-
clude from their comparison with data derived from nor-
mal populations and cohorts of RA patients not treated with
biologics that the reported malignancy rates were not high-
er in patients treated with abatacept. Hochberg and col-
leagues analysed the data of a total of 12,132 patient-years
of exposure and reported similar results [21].
Acute infusion events
In the long-term safety analysis, Hochberg and colleagues
assessed the IRs of acute infusion reactions with abatacept
in 3,755 patients with a total exposure of roughly 9,300
patient-years [21]. The IRs of acute infusion events in the
short term (6–12 months) were comparable between abata-
cept (11.6%) and placebo (9.8%). The proportion of pa-
tients experiencing infusion events decreased considerably
in year 2 (2.01%) and continued to decrease steadily over
time.
Combination with anti-TNFα
Weinblatt and colleagues investigated the efficacy and
safety of abatacept in combination with etanercept in 121
patients with active RA during a 1-year randomised,
placebo controlled, double-blind phase, followed by an
open-label long-term extension lasting 2 years, entered by
80 patients [24]. The combination of abatacept and etaner-
cept was associated with a significantly increased risk for
serious adverse events at 1 year compared to placebo and
etanercept, while the clinical benefit was limited. Based on
this trial, the manufacturer, Swissmedic and EMA recom-
mend not combining abatacept with an anti-TNF agent.
Review article: Current opinion Swiss Med Wkly. 2012;142:w13581
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 7
Vaccinations
A study in healthy volunteers suggested that abatacept may
blunt immune responses to vaccination [25]. In a sub-study
of the ARRIVE trial, Schiff and colleagues evaluated the
immune response to influenza immunisation in 20 abata-
cept patients with active RA [26]. They were vaccinated
7 days prior to an abatacept dose with the current WHO
trivalent influenza vaccine. A total of 55, 50 and 35% pa-
tients mounted a response to the H1N1, H3N2 and influ-
enza B strains respectively. Ribeiro and colleagues invest-
igated the humoral response to H1N1 influenza vaccination
in 11 RA patients treated with abatacept plus MTX and in
matching controls (33 RA patients treated with MTX and
33 healthy controls) [27]. Only 9% of patients treated with
abatacept plus MTX achieved seroprotection as compared
to 58% of patients with MTX alone (19/33) and 70% of
healthy subjects (23/33). Schiff and colleagues investigated
the response to pneumococcal vaccine in 21 RA patients
treated with abatacept in a sub-study of the ARRIVE trial
[28]. 81% of patients mounted an immune response to at
least one serotype.
In summary, abatacept appears to significantly suppress
vaccination responses, particularly to influenza antigens.
Data from patient registries will be necessary to define the
protective effect of influenza vaccination during treatment
with abatacept.
Surgical interventions
Practical concerns revolve mainly round intra- or postoper-
ative infections and wound healing. Theoretically, abata-
cept may contribute to both. However, there have been no
reports on postoperative infections or on delayed wound
healing so far. As controlled studies do not specifically
address such questions, patient registries will need to fill
these gaps.
Pregnancy
To date there are no data on the effect of abatacept on hu-
man pregnancy. It should be borne in mind that abatacept
crosses the placenta. In animal studies, no teratogenic ef-
fects have been registered in doses up to 20fold the doses
used in humans. The manufacturer advises against preg-
nancy during therapy and recommends discontinuation of
abatacept at least 10 weeks before a planned pregnancy.
Anti-nuclear and anti-DNA antibodies
Schiff and colleagues investigated the incidence of anti-
nuclear (ANA) and anti-DNA antibody seropositivity and
immunogenicity in RA patients treated with abatacept [29].
The proportion of patients with active treatment who deve-
loped ANA and anti-DNA antibodies was 3–5 times lower
as compared to those treated with placebo. Interestingly,
no antibodies against abatacept were observed during this
period.
Application mode and frequency
Abatacept is given intravenously at a dosage of approxim-
ately 10 mg/kg (<60 kg: 500 mg, >60 kg: 750 mg, >100 kg:
1000 mg). It is solubilised in 10 ml of aqua ad iniectabilia
and then dispersed in 90 mL isotonic NaCl. Infusions last
30 minutes. The second and third infusions are scheduled
at biweekly, all following administrations at monthly inter-
vals.
Conclusions and recommendations
Efficacy and safety
Abatacept is effective in MTX-naïve patients and in pa-
tients with inadequate response to non-biologic DMARDs
or to TNF inhibitors. The efficacy of abatacept is compar-
able to other biologic agents. While TNF inhibitors are still
widely used and recommended as first choice biologics in
the treatment of RA [30], the available data may support
the use of abatacept as a first line biologic agent. From a
clinical perspective, the favourable safety profile of abata-
cept, in particular regarding serious infections, is of in-
terest. However, it has to borne in mind that rare side ef-
fects, e.g. effects on malignancies, call for long-term data
from patient registries. Currently, we recommend the use
of abatacept in combination with MTX or – in the case of
MTX side effects or intolerance – in combination with an-
other conventional DMARD, as there is not sufficient data
to support the use of abatacept in monotherapy.
Onset of action
Disease activity parameters such as CRP or swollen/tender
joints may start to improve within two months after ini-
tiation of abatacept treatment in patients with early RA.
However, clinical effectiveness should not be evaluated be-
fore 3 months of treatment.
Abatacept as first-line biologic
Treatment should be stopped if the patient remains active
(HDAS, i.e. DAS >5.1) at the end of 3 months of treatment,
unless there is evidence of important improvement, e.g., a
drop in activity of at least 20% in DAS28. In the event
of an intercurrent problem such as surgery or an infection,
leads to interruption of therapy, the time period of 3 months
should be extended accordingly. On the other hand, if the
patients have achieved low disease activity (LDAS), the
chance of achieving remission in the coming months is
good (67.9%) and treatment should be continued. The same
Table 1: Overview of clinical abatacept trials referred to in this publication.
Clinical Phase Study Study duration and design Patient population Patients treated
IIb IM101-100 12 months, double-blind MTX inadequate responders 339
AIM 12 months, double-blind MTX inadequate responders 638
ATTEST 12 months, double-blind MTX inadequate responders 431
ATTAIN 6 months, double-blind Anti-TNF inadequate responders 391
ASSURE 12 months, double-blind DMARD inadequate responders 1441
III
ARRIVE 6 months, open-label Anti-TNF inadequate responders 1285
IIIb AGREE 12 months, double-blind MTX-naive patients with poor prognostic factors 509
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applies to patients with moderate disease activity after
3 months, given the likelihood of achieving low disease
activity or remission of 61.4%. However, response should
be monitored every 3 months, and therapy should be
stopped in the absence of further improvement.
Abatacept as second or third-line biologic
When used after previous failure of other biologics, the
treatment should be continued after 3 months even if the
patient is still in high disease activity. In this case a treat-
ment assessment and decision should be made after 6
months.
Glucocorticoids
Glucocorticoids should be introduced or increased in
dosage to bridge the time to a clinically meaningful effect
of abatacept. We also recommend intra-articular injections
into joints with persistent arthritis during treatment with
abatacept.
Surgical interventions
The interval between the last infusion of abatacept and the
scheduled surgery must be decided on an individual basis.
A host of factors may influence the chosen interval, in-
cluding activity of joint disease, concomitant immunosup-
pression (e.g. with glucocorticoid therapy), diabetes mel-
litus, history of infections, type of surgical procedure and
so forth. In uncomplicated cases with the RA in remission,
we recommend planning surgery at the point in time of the
following infusion and delaying the continuation of abata-
cept therapy until wound healing is complete.
Pregnancy
Due to the lack of data, no statement on the compatibility
of abatacept and pregnancy can be made. It should also be
borne in mind that abatacept crosses the placenta and will
accumulate in the foetus if administered during pregnancy.
The manufacturer advises against pregnancy during ther-
apy and recommends discontinuation of abatacept at least
10 weeks before a planned pregnancy.
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Figures (large format)
Figure 1
Mode of action of abatacept. By binding to CD80/86, abatacept blocks the interaction of CD80/86 and CD28 on the APC and T cell, respectively.
The co-stimulatory pathway leading to T-cell activation is inhibited and processes in the inflammatory cascade are downregulated, resulting in
normalized levels of cytokines and autoantibodies, and inhibition of osteoclast activity. APC: antigen presenting cell (e.g., macrophages,
dendritic cells, B cells); MHC: major histocompatibility complex; TCR: T-cell receptor; RF: rheumatoid factor; TNF: tumour necrosis factor; IFN:
interferon; IL: interleukin; anti-CCP: anti-cyclic citrullinated peptide; RANK: receptor activator of NF-κB; MMPs: matrix metalloproteinases.
Figure 2
Median time to at least 50% improvement in individual ACR core components (LOCF). Figure based on data of the AGREE study as reported by
Durez et al. [18]. CRP: C-reactive protein; TJC: tender joint count; SJC: swollen joint count; MDGA: physician’s global assessment; PGA:
patient’s global assessment.
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